All analyses
AI analysis

Asiri Surgical Hospital PLC: research report

Fairly valuedbullishOct 6, 2026

Evidence points bullish: profit rose 11.6% while shares trade at the cheapest P/B in record. The catch is that annual operating cash conversion was only 0.33 times.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bullish

  • June-quarter net profit rose 11.6% year-on-year, ahead of 7.4% revenue growth.
  • The P/B is 0.71 times, the cheapest day in the record since February 2012.
  • Annual debt fell to LKR 1.8 billion from LKR 2.4 billion.

Against this. Operating cash conversion was only 0.33 times in FY2026, so much of the reported operating profit had not arrived as cash.

Operating margin
18.1%
latest quarter
Net margin
15.4%sector 13.0%
from 12.1% a year earlier, revenue +17.6%
Return on equity
12.0%
twelve months to Sep 30, 2026, unaudited
P/E
7.0sector 11.8
earnings Rs 1.84 per share, year to Sep 2026
P/B
0.83sector 1.36
book Rs 15.34 per share
Dividend yield
0.00%sector 0.00%
trailing twelve months

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Oct 6, 2026. Sector figures are the median of 6 listed companies in the same sector.

Overview

Asiri Surgical Hospital operates a private surgical hospital with more than 155 beds, spanning routine and complex procedures across multiple specialist disciplines. The key operating change is that June-quarter profit grew faster than revenue, while gross margin matched its best June-quarter reading, supporting the moderately undervalued starting case despite a severe share-price retreat.

Price performance

At LKR 10.00 on 6 October 2026, AMSL had fallen 28.1% over three months, against a 6.5% fall in the ASPI. The one-year decline was 17.3%, versus 3.2% for the index, so the weakness has been materially greater than the broad market's.

The adjusted price sits at the bottom of its 52-week range and 58.3% below its high. The three-year record shows four falls of 15% or more, the deepest 58%, which has not yet recovered; this is a record of unusually large retreats, not a price forecast. Recent 60-day volatility is 36.5% below its own one-year norm, while 20-day volume is 36.2% above the preceding 60-day pace.

Median daily turnover was LKR 1.7 million. A LKR 1 million order is about 58% of what trades on a typical day, a large part of a day's trading.

Valuation

The shares trade on 6.2 rupees for every rupee of trailing profit, compared with a healthcare-peer median P/E of 12.9 times. P/B is 0.71 times, meaning a buyer pays 71 cents for each rupee of net assets, against a sector median of 2.09 times; the trailing ROE is 11.5%, so the discount is not accompanied by a low single-digit return on equity.

Against its own record, the P/B is the cheapest day in the record since February 2012 and the P/E is cheaper than 95% of days since February 2012. A buyer at this price is relying on earnings that were not dominated by the latest quarter: it supplied 23.2% of trailing EPS, and using its year-ago margin would change the P/E only from 6.2 to 6.3 times.

There is no current dividend yield and no dividend is on record in the last two years. The latest recorded payout was LKR 0.30 per share in FY2025, versus LKR 2.10 in FY2022, so the low valuation rests on earnings and asset value rather than income.

News and sentiment

Direct coverage is thin: one material article in the past 90 days was negative. It reported on 17 August that Softlogic Holdings' tax dispute involving Asiri Surgical Hospital remained under appeal; the article provides no amount for ASH, so its earnings effect cannot be sized.

There are no confirmed or pending corporate actions in the supplied record, and no dividend is on record in the last two years.

Financials

June-quarter revenue rose 7.4% year-on-year to LKR 2.0 billion and net profit increased 11.6% to LKR 226 million, leaving more profit for each rupee of hospital revenue. Gross margin was 43.2%, unchanged from 43.2% a year earlier and among its best June readings, ranking second of six. Operating margin is not available for the latest quarter, while the year-ago reading was 17.3%; therefore an operating-margin comparison cannot be made. Net margin was 11.1%, versus 10.7% a year earlier, and ranked a middling fourth of six June quarters.

The twelve months to June 2026 produced LKR 7.9 billion of revenue and a 12.6% net margin. The latest audited year to March 2026 recorded net profit of LKR 940 million, up from LKR 374 million, while equity attributable to owners reached LKR 7.6 billion. Shares outstanding were unchanged at 528.5 million between the latest balance sheet and today, so the reported per-share figures are not being mechanically altered by a corporate action.

Risks

The principal financial risk is cash backing: FY2026 operating cash flow covered only 0.33 times operating profit and free cash flow was negative LKR 95 million. Reported profit therefore did not translate fully into cash after working capital and capital spending, which limits how much comfort can be taken from the earnings recovery alone.

Debt was LKR 1.8 billion, equal to gearing of 24.2% of owners' equity, down from 37.1% a year earlier. Interest cover was 4.78 times, meaning operating profit covered the interest bill nearly five times, but the current ratio was 1.09 times: short-term assets, including receivables and supplies, only modestly exceeded bills due within a year. Minority shareholders received 13.4% of FY2026 group profit, so group profit is larger than the profit attributable to the ordinary shares being valued.

A separate unresolved risk is the tax dispute involving ASH reported on 17 August; the amount and potential financial consequence were not disclosed in the supplied coverage.

Outlook

As at 6 October 2026, the next specific event is the September 2026 interim-quarter filing, expected between 6 and 14 November. It will show whether the June pattern of revenue growth, stable gross margin and faster profit growth continued, and will supersede the June-quarter figures used here.

The data cannot quantify the financial exposure from the tax appeal. Healthcare policy developments described in the sector backdrop concern state hospital control and funding, not an identified action affecting ASH, so they do not establish an earnings outcome for the company.

About this report. Generated on Oct 6, 2026 from market data up to Oct 6, 2026, 1 material news articles over 90 days and financials to Jun 30, 2026, and scored 65 of 100 on value (moderately undervalued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports